Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows
15 Novembre 2023 - 2:30PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
that it had entered into an agreement with Elta 90 to distribute
Quantum-Si’s groundbreaking Platinum™ instrument and consumables in
Southeast Europe as demand grows for the first of its kind
next-generation protein sequencing™ platform.
This agreement between Quantum-Si and ELTA 90 holds immense
promise for accelerating scientific research by delivering the game
changing tool, Platinum, which interrogates proteins with
single-molecule amino acid resolution.
“We are thrilled to partner with ELTA 90 in this venture. The
synergy between Quantum-Si and ELTA 90 represents a major stride
toward expanding the field of proteomics,” explained Quantum-Si
Chief Executive Officer Jeff Hawkins. “This partnership will make
our affordable, benchtop instrument even more accessible, putting
Platinum’s unique technology within arm’s reach of scientists in
every lab, everywhere.”
“ELTA 90 is once again on the threshold of an exciting, new
journey. We look forward to working with Quantum-Si to unleash the
power of next-generation protein sequencing™ in labs throughout
Southeast Europe,” expressed Theodor Zamfirov, M.D., Chief
Executive Officer of ELTA 90. “Together, we’re poised to redefine
the boundaries of science and innovation, creating a brighter
future for researchers.”
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com
About ELTA 90
ELTA 90, a Bulgarian company establishment in 1999, has
consistently proven its commitment to innovation and the
advancement of science. ELTA 90 offers a wide range of high-quality
laboratory equipment, reagents, consumables, specialized diagnostic
and research tests, and laboratory furniture. ELTA 90’s unwavering
dedication to providing complete solutions in immunology, clinical
laboratory, microbiology, virology, and rapid diagnostics has made
them a trusted partner in the industry. Learn more at:
www.elta90.com
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the impact of COVID-19 on the
Company's business; the inability to maintain the listing of the
Company's Class A common stock on The Nasdaq Stock Market; the
ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition and the ability of the Company to grow and manage
growth profitably and retain its key employees; our ongoing
leadership transition; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum™ protein
sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231115504371/en/
Investors Jeff Keyes, CFO ir@quantum-si.com
Media Katherine Atkinson, SVP of Commercial Marketing
media@quantum-si.com
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Quantum Si (NASDAQ:QSI)
Storico
Da Set 2023 a Set 2024